Blueprint

R&D Blueprint

The R&D Blueprint is a global strategy and preparedness plan that allows the rapid activation of research and development activities during epidemics. Its aim is to fast-track the availability of effective tests, vaccines and medicines that can be used to save lives and avert large scale crises. With WHO as convener, the broad global coalition of experts who have contributed to the Blueprint come from medical, scientific and regulatory backgrounds. WHO Member States welcomed the development of the Blueprint at the World Health Assembly in May 2016.

About us

Key actions by disease

R&D Blueprint and Monkeypox

R&D Blueprint and Ebola/Marburg

R&D Blueprint and Lassa Fever

R&D Blueprint and MERS-CoV

R&D Blueprint and Nipah Virus

R&D Blueprint and Zika

Events

Useful resources

25 – 26 October 2022

SAVE THE DATE - Accelerating the licensure of Lassa vaccines: Generating robust evidence on vaccine efficacy and safety

29 – 30 August 2022

Scientific strategies from recent outbreaks to help us prepare for Pathogen X

A technician prepares a microscopic slide in a laboratory

Research and Development (R&D) Roadmaps

A scientist woman pulling out a tube from a freezer for genetic testing

Prioritizing diseases for research and development in emergency contexts

Heath providers vaccinating children in a community

Good Participatory Practice

Related activities

Infographics

1 June 2022

Solidarity Trial Vaccines (STV)

Documents

All →

The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their...

Download

The document provides an overview of the different observational studies that are being conducted to assess the effectiveness of COVID-19 vaccination,...

Download

The WHO is tracking advances and ongoing progress from research and development to clinical trials of vaccines for Sudan virus (SUDV).The tracker provides...

Download

covid19 nma summary results publication cover

Since the early months of the COVID-19 pandemic (March 2020), the COVID-NMA initiative, an international initiative working in conjunction with the...

Download

Publications

All →

This large, international, randomized controlled clinical trial is designed to enable an expeditious, agile and concurrent evaluation of the benefits and...

Download

There has been some suggestions for the inclusion of Favipiravir in the Solidarity trial.

Download

Currently, there are no licensed vaccines for the prevention of COVID 19. While efforts continue to develop effective vaccines, it is pertinent to examine...

Download